tiprankstipranks
Trending News
More News >
Laboratorios Farmaceuticos Rovi (ES:ROVI)
:ROVI
Advertisement

Laboratorios Farmaceuticos Rovi (ROVI) Stock Statistics & Valuation Metrics

Compare
27 Followers

Total Valuation

Laboratorios Farmaceuticos Rovi has a market cap or net worth of €2.68B. The enterprise value is €2.86B.
Market Cap€2.68B
Enterprise Value€2.86B

Share Statistics

Laboratorios Farmaceuticos Rovi has 51,235,764 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,235,764
Owned by Insiders
Owned by Institutions

Financial Efficiency

Laboratorios Farmaceuticos Rovi’s return on equity (ROE) is 0.24 and return on invested capital (ROIC) is 19.73%.
Return on Equity (ROE)0.24
Return on Assets (ROA)0.16
Return on Invested Capital (ROIC)19.73%
Return on Capital Employed (ROCE)0.27
Revenue Per Employee347.63K
Profits Per Employee80.88K
Employee Count2,197
Asset Turnover0.92
Inventory Turnover0.86

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio19.4
PS Ratio0.00
PB Ratio4.72
Price to Fair Value5.64
Price to FCF34.75
Price to Operating Cash Flow19.65
PEG Ratio8.76

Income Statement

In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of 763.75M and earned 136.88M in profits. Earnings per share was 2.67.
Revenue763.75M
Gross Profit478.35M
Operating Income179.54M
Pretax Income177.69M
Net Income136.88M
EBITDA207.69M
Earnings Per Share (EPS)2.67

Cash Flow

In the last 12 months, operating cash flow was 141.58M and capital expenditures -61.50M, giving a free cash flow of 80.08M billion.
Operating Cash Flow141.58M
Free Cash Flow80.08M
Free Cash Flow per Share1.56

Dividends & Yields

Laboratorios Farmaceuticos Rovi pays an annual dividend of €0.935, resulting in a dividend yield of 1.72%
Dividend Per Share€0.935
Dividend Yield1.72%
Payout Ratio55.77%
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.43
52-Week Price Change-37.36%
50-Day Moving Average53.67
200-Day Moving Average58.02
Relative Strength Index (RSI)41.39
Average Volume (3m)117.81K

Important Dates

Laboratorios Farmaceuticos Rovi upcoming earnings date is Nov 6, 2025, TBA (Confirmed).
Last Earnings DateJul 24, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend DateJul 14, 2025

Financial Position

Laboratorios Farmaceuticos Rovi as a current ratio of 3.14, with Debt / Equity ratio of 18.37%
Current Ratio3.14
Quick Ratio1.03
Debt to Market Cap0.03
Net Debt to EBITDA0.42
Interest Coverage Ratio90.31

Taxes

In the past 12 months, Laboratorios Farmaceuticos Rovi has paid 40.81M in taxes.
Income Tax40.81M
Effective Tax Rate0.23

Enterprise Valuation

Laboratorios Farmaceuticos Rovi EV to EBITDA ratio is 15.96, with an EV/FCF ratio of 43.58.
EV to Sales4.34
EV to EBITDA15.96
EV to Free Cash Flow43.58
EV to Operating Cash Flow23.97

Balance Sheet

Laboratorios Farmaceuticos Rovi has €29.31M in cash and marketable securities with €108.38M in debt, giving a net cash position of €79.08M billion.
Cash & Marketable Securities€29.31M
Total Debt€108.38M
Net Cash€79.08M
Net Cash Per Share€1.54
Tangible Book Value Per Share€10.68

Margins

Gross margin is 64.46%, with operating margin of 23.51%, and net profit margin of 17.92%.
Gross Margin64.46%
Operating Margin23.51%
Pretax Margin23.27%
Net Profit Margin17.92%
EBITDA Margin27.19%
EBIT Margin23.53%

Analyst Forecast

The average price target for Laboratorios Farmaceuticos Rovi is €90.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€90.00
Price Target Upside65.44% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-1.49%
EPS Growth Forecast4.04%

Scores

Smart Score1
AI Score73.9
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis